Skip to Main Content
Contribute Try STAT+ Today

Two years ago, French regulators made a surprising decision, overruling one of their own expert committees to approve a controversial drug for combating alcoholism. But the move has triggered an increasingly heated debate over a key clinical trial, which critics argue raises troubling questions about transparency, as well as the extent to which patient groups may have influenced the regulator.

At issue is a drug called baclofen, a decades-old treatment for muscle spasms that is increasingly used in France on an off-label basis to help people control their drinking. In an attempt to appease patients, French regulators temporarily authorized off-label use in 2014, while awaiting the results of two clinical trials. But one of these studies took five years to be published and has proven problematic.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.